Vaccines against encapsulated bacteria: a global agenda

Rev Infect Dis. 1987 Jan-Feb;9(1):176-88. doi: 10.1093/clinids/9.1.176.

Abstract

The World Health Organization (WHO) asked the authors to create a comprehensive program for the development of vaccines against encapsulated bacteria as a guide for the WHO Programme on Vaccine Development. The goal is a new generation of safe, inexpensive, and easily administered vaccines that are immunogenic in infancy and provide prolonged immunity in the vaccinate, secondary immunization to community members not reached in the initial application, and/or herd immunity. The approach is to capitalize on advances in molecular biology, biochemistry, and immunology, and the agenda developed addresses the five genera that cause most morbidity in less-developed areas of the world: Neisseria, Streptococcus, Staphylococcus, Haemophilus, and Pseudomonas. Three strategic areas for study are emphasized: existing polysaccharide vaccines, natural immunity and pathogenesis, and evaluation of new or speculative alternative approaches. It is hoped that this agenda will stimulate the widest possible participation in this global initiative.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Bacterial Capsules
  • Bacterial Vaccines*
  • Escherichia coli / immunology
  • Haemophilus / immunology
  • Haemophilus Vaccines*
  • Humans
  • Neisseria / immunology
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial*
  • Pseudomonas / immunology
  • Staphylococcus / immunology
  • Streptococcus / immunology
  • World Health Organization

Substances

  • Bacterial Vaccines
  • Haemophilus Vaccines
  • Haemophilus influenzae type b polysaccharide vaccine
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial